Fig. 6
From: Enhancing recurrence risk prediction for bladder cancer using multi-sequence MRI radiomics
Decision curve analysis for the clinical model, radiomics model, and combined model for BCa recurrence risk assessment. Note: the Y-axis represents the net benefit; the X-axis represents the threshold probability. The net clinical benefit of the radiomics-clinical model was higher than that of the radiomics and clinical model across all risk threshold probabilities and higher than that of the two reference cases, namely the red line of “All” (all patients considered as recurrence) or the yellow line of “None” (all patients considered as no recurrence)